The effects of tranexamic acid on bleeding control

The effects of tranexamic acid on bleeding control during and after percutaneous nephrolithotomy (PCNL)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180625040232N4

Enrollment

108

Registered

2020-06-17

Start date

2013-08-23

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding. Hemorrhagic disorder due to extrinsic circulating anticoagulants

Interventions

Intervention 1: Intervention group: In the intervention group, 1 gr of tranexamic acid (Caspian Tamin Pharmaceutical Company) is diluted in 100 ml normal saline and injected into nephrostomy drain (in

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18-65 years ASA class >III Not having coagulopathy

Exclusion criteria

Exclusion criteria: Need to embed Double J Stent Prediction of need to transfusion during surgery Patients with coagulopathy

Design outcomes

Primary

Measure	Time frame
Bleeding. Timepoint: 24 hours before surgery and 48 hours after surgery. Method of measurement: Blood sampling.	—

Secondary

Measure	Time frame
Hospital stay days. Timepoint: Once, at the time of discharge. Method of measurement: Calculating hospital stay days from admission to discharge.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaman Farshid

Oroumia University of Medical Sciences

samanf63@gmail.com+98 44 3346 9931

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026